skip to main content



Catalogue No.


Cell Line Name


Cell Line Description

The MCF7/164R-7 cells are resistant to the pure steroidal antiestrogen fulvestrant (ICI 182,780) and can be maintained continuously in growth medium with 100 nM fulvestrant

General Info



Unique to ECACC


Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.


Tissue of Origin



Polygonal epithelia, adherent

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 10
D3S1358: 16
D5S818: 11,12
D7S820: 8,9
D8S1179: 10,14
D13S317: 11
D16S539: 11,12
D18S51: 14
D21S11: 30
FGA: 23,25
Penta D: 12
Penta E: 7,12
TH01: 6
TPOX: 9,12
vWA: 14,15



Culture Conditions

Cell Type


Subculture Routine

Split sub-confluent cultures at 70-80% confluency. Subculture cells using 0.05% trypsin/EDTA solution and soya bean trypsin inhibitor or TrypLE Express™1X), without phenol red, and wash with phosphate- buffered saline (PBS). Pellet cells by centrifugation and re-suspend in growth medium. Initiate the culture at a dilution of approximately 1:3 to 1:6 i.e. seeding at 2-4x10⁴ cells per cm². Incubate cultures in 5% CO₂ in air at 37°C. Recommend media changes every 2-3 days per cm². Cells can be cryopreserved in either a mixture of cell line conditioned medium (45%) and fresh serum free-medium (45%) with 10% dimethyl sulphoxide (DMSO) or 90% Foetal Bovine Serum (FBS) and 10% dimethyl sulphoxide (DMSO). It is recommended that upon resuscitation the cells are washed in phosphate-buffered saline (PBS) or serum-free medium, pelleted by centrifugation and re-suspended in growth medium prior to initiation of culture.

Culture Medium

Phenol red free DMEM/F12 (1:1) supplemented with 1% FCS, Glutamax 2.5 mM and 6 ng/ml insulin. Supplemented with 100nM fulvestrant to maintain resistance. Recommend media changes every 2-3 days.

Growth Mode


Additional Info


Ximbio (formerly known as Cancer Research Technologies Limited)

Country of Origin


Hazard Group (ACDP)

Hazard Group (ACDP) 2



Thrane et al. 2014. Oncogene. PMID: 25362855 Sonne-Hansen et al. 2010. Breast Cancer Res Treat. 121(3):601-13. PMID: 19697122Frogne et al. 2009. Breast Cancer Res Treat. 114(2):263-75. PMID: 18409071


Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-79. PMID: 17061041 Larsen et al. 1997. Int J Cancer. 72(6):1129-36. PMID: 9378550. Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-34. PMID: 7759159

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: MCF7/164R-7 (ECACC 16022505).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.